Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte, exercised employee stock options covering 45,767 shares and acquired common stock, then reported sale transactions totaling 47,954 shares of common stock on July 31 and August 3, 2026, pursuant to a Rule 10b5-1 trading plan.
The exercised options included grants with exercise prices of $61.18, $72.27 and $105.43 per share. Footnotes state his reported holdings also include 59,537 additional shares underlying unvested restricted stock units.
Patrick A. Mayes filed to sell common stock of Incyte Corporation through Morgan Stanley Smith Barney LLC. The planned transaction covers 6,055 shares of common stock, related to a stock option exercise, with an aggregate market value of $729,203.65 as of the filing. The shares are listed on NASDAQ and the transaction date is August 3, 2026. During the prior three months, Mayes also sold 41,899 shares of common stock for an aggregate value of $5,005,186.06 on July 31, 2026.
Incyte Corporation is registering a planned resale of common stock under Rule 144. The filing covers 41,899 common shares, with an aggregate market value of 5,005,186.06, proposed to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ on or after July 31, 2026. The shares include 39,712 shares acquired from the issuer via stock option exercises for cash on July 31, 2026 and 2,187 shares acquired as restricted stock from the issuer on July 15, 2026.
A shareholder of Incyte Corporation (INCY) has filed to potentially sell 15,888 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The planned sale, with an aggregate market value of $1,901,833.32, is listed for NASDAQ with an anticipated sale date of 07/31/2026. The securities include 12,181 restricted stock shares dated 07/14/2024 and 3,707 performance shares dated 07/14/2026.
Incyte Corporation reported strong profitability for the three and six months ended June 30, 2026. Total revenues were $1,674,039 (in thousands) for the quarter and $2,946,715 (in thousands) for the first half of 2026, compared with $1,215,529 and $2,268,427 (in thousands) in 2025.
Growth was driven by higher net product sales of $2,592,633 (in thousands), including JAKAFI net sales of $1,574,414 (in thousands) and OPZELURA net sales of $592,751 (in thousands). OPZELURA results include a one-time, non-cash $246.0 million benefit from reversing Medicaid rebate accruals following a settlement with CMS. Product royalty revenues also increased to $325,882 (in thousands).
Net income rose to $585,605 (in thousands) for Q2 and $888,935 (in thousands) for the first half, with diluted EPS of $2.81 and $4.28, respectively. The effective tax rate declined to 18.8% for the six-month period, helped by tax credits, foreign tax effects and U.S. tax law changes. Incyte ended June 30, 2026 with cash and cash equivalents of $3,982,375 (in thousands) and generated operating cash flow of $877,013 (in thousands). Subsequent to quarter-end, it agreed to acquire Vega Therapeutics for $1.25 billion in cash plus up to $750.0 million in sales milestones, which it expects to expense largely as in-process R&D in the third quarter of 2026.
Incyte reported strong second quarter 2026 results, with total revenue of $1.67 billion, up 38% year over year, and total net sales of $1.49 billion, up 40%. Jakafi net sales were $817 million, up 7%. Opzelura net sales reached $450 million, up 173%, including a $246 million one-time, non-cash benefit from the CMS agreement; excluding this, total net sales grew 17%. Hematology and Oncology portfolio net sales rose 69% to $222 million. GAAP net income was $585.6 million and GAAP diluted EPS $2.81, while non-GAAP diluted EPS was $3.09. Cash, cash equivalents and marketable securities were $4.5 billion as of June 30, 2026.
Management updated 2026 guidance, raising total net sales to $5,130–$5,260 million from $4,770–$4,940 million, Opzelura net sales to $1,050–$1,100 million, and Hematology and Oncology net sales to $860–$890 million, reflecting the Opzelura CMS settlement’s estimated $300–$310 million incremental impact and continued portfolio growth. GAAP R&D and SG&A operating expense guidance increased to $4,915–$4,995 million (non-GAAP $4,625–$4,695 million), largely due to the Vega Therapeutics acquisition, including approximately $1,270 million of IPR&D expense and $50 million of additional R&D for latarcibart. The company also highlighted multiple late-stage trials and regulatory milestones across hematology, oncology and inflammation, including Jakafi XR’s U.S. approval, Monjuvi/Minjuvi submissions in newly diagnosed DLBCL, a positive CHMP opinion for Opzelura in moderate atopic dermatitis in Europe, and ongoing Phase 3 development of latarcibart in von Willebrand disease.
Michael James Morrissey, EVP and Head of Technical Operations at Incyte, received two equity awards on July 23, 2026. He was granted 6,426 stock options with a $116.69 exercise price, vesting 25% after one year then monthly over three years, expiring July 22, 2036. He also received 8,999 performance shares, each representing the right to receive up to 200% of one common share based on relative three-year TSR versus a fixed peer group, with earned shares vesting on the third anniversary of the grant, subject to continued service.
Incyte Corp EVP and Head of Incyte International Heeson Lee received new equity awards on July 23, 2026: 15,423 employee stock options at a $116.69 exercise price, expiring in 2036, and 13,498 performance shares, all reported as directly owned.
The options vest 25% after one year, then monthly over three years. Each performance share represents up to 200% of one common share, earned on relative total shareholder return over a three-year period starting January 1, 2026, with earned shares vesting on the third grant anniversary.
Incyte Corp reported that Principal Accounting Officer Tray Thomas received equity awards on July 16, 2026. He was granted 2,834 restricted stock units (RSUs), vesting 25% annually over four years, and 4,079 employee stock options with a $116.65 exercise price, expiring July 15, 2036, vesting 25% after one year then monthly over three years. Following these grants he directly holds 21,699 common shares, including 13,070 shares issuable from previously reported unvested RSUs.
Steven H. Stein, Incyte's CMO and Head of Late-Stage Development, reported July 16, 2026 equity activity including grants of 9,798 restricted stock units, 24,496 performance shares, and 42,298 stock options with an exercise price of 116.6500 per share, plus a sale of 1,877 common shares at 114.7300 per share. These transactions were made under a Rule 10b5-1 trading plan. The RSUs vest 25% annually over four years, the options vest over four years in 37 installments, and performance shares may earn up to 200% of one share based on three-year relative TSR versus a peer group.